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Abstract Occipital nerve block (ONB) has been used in
several primary headache syndromes with good results.
Information on its effects in facial pain is sparse. In this
chart review, the efﬁcacy of ONB using lidocaine and
dexamethasone was evaluated in 20 patients with cranio-
facial pain syndromes comprising 8 patients with trigemi-
nal neuralgia, 6 with trigeminal neuropathic pain, 5 with
persistent idiopathic facial pain and 1 with occipital neu-
ralgia. Response was deﬁned as an at least 50% reduction
of original pain. Mean response rate was 55% with greatest
efﬁcacy in trigeminal (75%) and occipital neuralgia
(100%) and less efﬁcacy in trigeminal neuropathic pain
(50%) and persistent idiopathic facial pain (20%). The
effects lasted for an average of 27 days with sustained
beneﬁts for 69, 77 and 107 days in three patients. Side
effects were reported in 50%, albeit transient and mild in
nature. ONBs are effective in trigeminal pain involving the
second and third branch and seem to be most effective in
craniofacial neuralgias. They should be considered in facial
pain before more invasive approaches, such as thermoco-
agulation or vascular decompression, are performed, given
that side effects are mild and the procedure is minimally
invasive.
Keywords Trigeminal neuralgia  Facial pain 
Trigeminal neuropathic pain  Occipital nerve block 
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Introduction
The use of occipital nerve block (ONB) has been propa-
gated in occipital and cervical pain syndromes and dates
back into the 1970s [1]. Its use was later established in
cervicogenic headache, where pain reduction following
occipital nerve block is currently considered part of the
diagnostic procedure [2–5]. Subsequently, ONBs were
used in other primary headache like migraine [5–8], cluster
headache [9–12] and chronic daily headache, respectively,
tension-type headache [9, 13] (for review see [14]). The
exact mechanisms by which ONB exerts its effects remain
uncertain. In occipital neuralgia, local perineural applica-
tion of anesthetics and steroids could cause a direct depo-
larisation and inhibition of neural excitability. However,
this would not explain the effect in headaches involving the
ﬁrst trigeminal branch. One potential explanation is the
concept of functional connectivity between high nocicep-
tive afferents (C1-3) and trigeminal nociceptive afferents
from the ﬁrst branch with convergence in the trigemino-
cervical complex (TCC) [15, 16]. The ONB is thought to
interfere with the subsequent sensitization developing
during the event of acute headache attacks, modulating the
excitability of second-order neurons receiving input from
both trigeminal and cervical afferents upon stimulation of
either afferent input [15, 16]. Recent studies additionally
suggest that trigeminal branches innervating the meninges
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target for therapeutic interventions such as ONB [17].
Despite the effective application in headaches involving
the ﬁrst trigeminal branch, little is known regarding efﬁ-
cacy of ONB in craniofacial neuralgias (apart from
occipital neuralgia), trigeminal neuropathic pain and per-
sistent idiopathic facial pain. More precisely, little is
known whether ONB is effective in painful conditions
involving the second and third maxillary branch. One
report dating back to the 1960s reported complete pain
relief in postherpetic neuralgia after alcohol blocks of the
greater occipital nerve in all six patients [18]. Three of
them had involvement not only of the frontal but also of the
mandibular and maxillary branch of the trigeminal nerve.
In another case report, one patient with neuropathic facial
pain in the ﬁrst and second trigeminal branch due to pro-
gressive facial hemiatrophy had sustained beneﬁt from a
single ONB with lidocaine and methylprednisolone for
4 months [19].
Consequently, patients attending our outpatient depart-
ment were identiﬁed who had medically intractable facial
pain and received uni- or bilateral occipital nerve blocks.
We wanted to elucidate whether:
1. ONB effects were principally conﬁned to the ﬁrst
trigeminal branch or would also extend to the second
and third branch.
2. ONB would be clinically meaningful effective in
craniofacial neuralgias, neuropathies and persistent
idiopathic facial pain
3. Differences in efﬁcacy were syndromal, i.e. more or
less efﬁcacious in neuralgias than in persistent facial
pain.
Patients and methods
Study design
Medical records of patients with facial pain or cranial
neuralgias who presented to the facial pain clinic of the
University Medical Centre Hamburg-Eppendorf between
December 2009 and July 2010 were reviewed. Only
patients who received an ONB in these conditions with
appropriate clinical documentation were included in this
retrospective chart review. Further inclusion criteria were:
diagnosis of craniofacial neuralgia, trigeminal neuropathic
pain or persistent idiopathic facial pain according to the
criteria given below, stable preventative medication during
follow-up period and at least 18 years of age. Patients were
treated with an ONB due to impairment by acute exacer-
bations of pain.
Patients
All patients had been seen by headache specialists (AM,
TPJ) who established a diagnosis of craniofacial neuralgia
including classical trigeminal neuralgia (IHS 13.1.1),
symptomatic trigeminal neuralgia (IHS 13.1.2) and occip-
ital neuralgia (IHS 13.8) and persistent idiopathic facial
pain (IHS 13.18.4) according to the current ICDH-II cri-
teria [20]. In trigeminal neuralgia, intense and brief pain
paroxysms occur in one or more divisions of the trigeminal
nerve lasting from less than a second to 2 min. These
stereotyped attacks are intense sharp or stabbing. Attacks
can be precipitated by trigger factors such as washing,
eating, drinking or talking. In addition, contact with trigger
areas such as the nasolabial fold or the chin can provoke
attacks, which can also occur spontaneously. Symptomatic
trigeminal neuralgia is deﬁned by the presence of a struc-
tural lesion other than a neurovascular compression.
Occipital neuralgia is deﬁned as a paroxysmal stabbing
pain in the distribution of the greater, lesser and/or third
occipital nerve with tenderness over the affected nerve.
ONBs typically ease the pain. Persistent idiopathic facial
pain is deﬁned as deep and poorly localized facial pain
which is present daily and for the entire or most of the day.
It is limited to one side of the face and frequently starts
around the nasolabial fold and the chin and is not associ-
ated to sensory loss or other physical abnormalities. Clin-
ical diagnostics including radiography of the face and the
jaws are unremarkable.
As no diagnostic criteria for trigeminal neuropathic pain
are given in the ICHD-II, the criteria by Zakrzewska [21]
had to be fulﬁlled. They deﬁne trigeminal neuropathic pain
as a continuous dull pain with sharp exacerbations in the
trigeminal area that may radiate beyond. It can be provoked
by contact with areas of allodynia and by light touch.
Subjective or objective sensory loss is typical and vasodi-
latation and swelling can occur.
Patients had been routinely contacted (by either OF or
PM) every 3–7 days after ONB and pain intensity and
relevant changes had been noted as part of the outpatient
clinics internal standard protocol in the medical ﬁles.
These outcomes were assessed during telephone contact
verbally as indicated by the patient. This routine was
implemented to ensure that patients without clinical
effects or exacerbation after transient improvement were
rapidly seen again to initiate alternative therapy. A total of
20 patients (7 males, 13 females, mean age 58.2 ± 20.4
years, range 21–89 years) were identiﬁed who had
received a total of 25 ONBs with appropriate documen-
tation. Detailed information on demographical data is
given in Table 1. One patient had been lost to follow-up
after 12 days (TNP4).
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123Table 1 Demographical data on patients who received occipital nerve blocks in facial pain
ID Age
(years)
Gender Diagnosis Branch Side Duration
(years)
Concomitant disease Current medication
TN1 72 F TN V2, V3 Right 10 Hypothyreoidism
Bronchial asthma
Chronic gastritis
Chronic paranasal
infection
Carbamazepine 400–600 mg
XR, L-thyroxine 75 mcg,
ranitidine 150 mg,
budesonide ? formeterol
inhalator
TN2 67 M TN (symptomatic) V2 Right 8 Multiple sclerosis
Intermittent tachycardia
–
TN3 70 M TN (symptomatic) V1, V2,
V3
Right 10 Encephalomyelitis
disseminata
Arterial hypertension
COPD
Carbamazepine 1,200 mg
TN4 84 F TN V2 Right 20 Percutaneous
thermocoagulation of
the trigeminal
ganglion in 07/06
with remaining
trigeminal
hypoesthesia
Arterial hypertension
Hyperlipidaemia
Thyroid dysfunction
Carbamazepine 400 mg,
nitredipine 20 mg,
tritamterene 50 mg, iodide
200 mcg, simvastatin 80 mg,
losartane 50 mg,
hydrochlorothiazide 12.5 mg,
doxycycline 200 mg
TN5 48 F TN (symptomatic) V3 Left 11 Symptomatic
trigeminal neuralgia
(right side) in the past
(complete remission)
Multiple sclerosis
(1992)
Bile duct stenosis of
suspected
autoimmune origin
Oxcarbazepine 1,800 mg,
azathioprine 75 mg,
interferon beta-1 44 mcg, oral
contraceptive, pantoprazole,
preceding week
4 9 1,000 mg
methylprednisolone i.v.
TN6 55 M TN V3 Right 1 History of alcohol
addiction for
20 years, currently
abstinent
Lumbar and cervical
disc herniation
Gabapentin 1,200 mg,
carbamazepine 300 mg,
baclofen 10 mg, disulﬁram
250 mg
TN7 89 F TN V2, V3 Right 25 Microvascular
decompression (1999)
Metoprololsuccinate 95 mg, L-
thyroxine 150 mcg,
candesartan 16 mg,
hydrochlorothiazide 12.5 mg,
cinnarizin e 20 mg,
dimenhydrinate 40 mg
TN8 59 F TN V2 Right 5 Arterial hypertension
Allergic reaction to
phenytoin
Prednisolon 80 mg, enalapril
2.5 mg, atenolol 25 mg
TNP1 62 F TNP V2 Left 20 Spondylolysis due to
scoliosis
Hypothyreoidism
L-thyroxine 80 mcg
TNP2 29 M TNP V2 Right 7 Attention deﬁcit
hyperactivity disorder
Chronic recurrent
sinusitis
Methylphenidate 30-40 mg,
gabapentin 900 mg, doxepine
25 mg
TNP3 43 F TNP V3 Right 8 Allergic asthma Gabapentin 3,600 mg/d,
salmeterol 50
mcg ? ﬂuticasone 500 mcg
inhalator
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As this was a chart review, no experimental design was
predeﬁned. Due to standard operating procedures and a
standardized documentation in our clinic, patients were
treated in a uniform manner. However, composition of the
local anesthetic and steroid mixture varied in some patients
and some received only unilateral blocks (see Tables 2, 3,
4, 5 for details).
A positive response to ONB was deﬁned as at least 50%
improvement of pain according to the patient’s global
rating at the ﬁrst telephone contact after ONB. If more than
one ONB was performed, mean improvement for all blocks
was calculated and the patient was classiﬁed as responder
only if mean improvement was at least 50%. All but 2
patients were contacted 3–5 days thereafter (FP1_4 and FP
4_2 on day 6). Data had been collected immediately after
the ONB and every 3–7 days thereafter. If the beneﬁt had
been less than 50% for more than 2 telephone visits, the
subject had been asked to visit the outpatient department
again on short notice or advised to take an alternative
therapy. Apart from improvement measured in percent of
baseline pain, pain intensity on a verbal rating scale (VRS)
from 0 (no pain) to 10 (worst imaginable pain) and sus-
ceptibility to triggers on a scale from 0 (unsusceptible to
triggers) to 10 (highly susceptible to triggers) had been
noted. Before ONB, the presence of local tenderness over
the greater occipital nerve had been tested bilaterally. After
ONB, the patient had been screened for the presence of
occipital hypoesthesia and asked whether the procedure
was painful. At follow-up, the patients had been routinely
asked about the degree of improvement, current pain
intensity, susceptibility to triggers, and side effects as part
of standard medical care. Additionally, they were asked
about any change in medication. As patients were con-
tacted on a regular basis with narrow intervals of 3–7 days,
outcome measures were determined solely by personal
contact and not by means of a diary.
Table 1 continued
ID Age
(years)
Gender Diagnosis Branch Side Duration
(years)
Concomitant disease Current medication
TNP4 80 M TNP V2 Left 1 Total knee replacement Metamizole PRN
TNP5_1-2
a 32 F TNP V1, V2 Right 2 Reconstruction of
cruciate ligament
Gabapentin 3,300 mg/d,
indometacin 50–200 mg,
topiramate 150 mg,
mirtazapine 15 mg,
pantoprazol 40 mg
TNP6 21 F TNP V2, V3 Right 3 Migraine without aura
Hypothyreoidism
Cholecystolithiasis
Duloxetine 120 mg,
pregabaline 300 mg,
metoprolol 100 mg
FP1_1-4
a 77 M FP V1–V3 Right 15 months Recurrent gastric ulcera
Chronic low back pain
Prostatic carcinoma
Unilateral kidney
resection due to tumor
Gabapentin 300 mg,
amitriptyline 60 mg,
omeprazol 40 mg
FP2 67 F FP V1–V3 Left 1 None Lamotrigine 3 9 100 mg,
amitriptyline 75 mg XR
FP3 77 M FP V2 Right
and
left
2 Perforated gastric ulcer –
FP4_1-2
a 55 F FP V2 Left 5 None Carbamazepine 600 mg,
amitriptyline 20 mg,
paracetamol up to 1,500 mg
FP5 21 F FP V2 Left 1 Chronic knee and lower
back pain
Obesity
Diclofenac 75 mg PRN
ON1 55 F ON C2 Left 1 week History of
subarachnoidal
hemorrhage
Depression
Pregabaline 100 mg
F female, M male, V1 ﬁrst trigeminal branch, V2 second trigeminal branch, V3 third trigeminal branch, FP persistent idiopathic facial pain, TN
trigeminal neuralgia, TNP trigeminal neuropathic pain, ON occipital neuralgia
a Patients received repetitive GON blocks. Baseline data are given only for the ﬁrst visit
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All occipital nerve blocks were administered by TPJ to
minimize variation. Injections were placed halfway on the
nuchal line between the occipital protuberance and the
mastoid process and above the occipital ridge [11, 13].
After the greater occipital nerve was located, local ten-
derness was evaluated bilaterally. All but 2 patients (FP2,
TN2) had received bilateral nerve blocks. Unilateral blocks
had been given on request of the patients (known cardiac
arrhythmia in TN2, explicit wish by FP2). A mixture of a
local anesthetic (Lidocaine-HCl 1 or 2%, B. Braun Mels-
ungen, Melsungen, Germany) and dexamethasone as ste-
roid (Fortecortin injekt 4 mg, Merck Pharma, Germany)
had been injected after protruding a 21-G needle until
periosteal contact was established and aspiration had been
negative. After 15 min, the presence of occipital hypoes-
thesia had been tested.
Statistical analysis
Patient data were entered into an Excel 2007 (Microsoft,
Redmond, WA, USA) spreadsheet for descriptive statistics.
For pairwise comparisons of metric data t tests (paired or
unpaired, two-tailed,) were used, categorical data were
analyzed using 2 9 2o r29 3 tables for Fisher’s Exact
test (SPSS 18.0) with p\0.05 regarded signiﬁcant. Graphs
were plotted with SigmaPlot2000 (Systat Software, Inc.
San Jose, CA, USA).
Results
A total of 25 ONBs were given to 20 patients with cra-
niofacial neuralgias, trigeminal neuropathic pain and per-
sistent idiopathic facial pain. Among them, 8 patients
suffered from trigeminal neuralgia (40%), 6 patients from
trigeminal neuropathic pain (30%), 5 patients from per-
sistent idiopathic facial pain (25%) and 1 patient from
occipital neuralgia (5%). The male:female ratio was 1:1.9.
The affected nerve branches are given in Table 1.
Response rates
A positive response with a global improvement of at least
50% pain from baseline according to the patient’s state-
ment was found in 11 out of 20 patients (55%; Fig. 1).
Response rates were highest in occipital neuralgia (1
patient with complete relief, i.e. 100%; Table 3) and tri-
geminal neuralgia with positive effects in 6 out of 8
patients (75%; Table 2; Fig. 2a). In trigeminal neuropathic
pain, 3 out of 6 patients had a positive response into ONBs
(50%; Table 4; Fig. 2b), in persistent idiopathic facial pain
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123only 1 out of 5 patients responded to ONB (20%; Table 5;
Fig. 2c). Two patients (TNP2 and FP1) reported
improvement to 40% despite unchanged pain intensities.
This constellation seemed implausible and consequently
their response was rated as being negative. As for patients
with multiple ONBs, TNP5 and FP1 were classiﬁed as
responders, FP4 as non-responder.
Fisher’s Exact test using a 2 9 3 table with response
(yes/no) versus type of facial pain (trigeminal neuralgia,
trigeminal neuropathic pain, persistent idiopathic facial
pain) yielded no signiﬁcant result (P = 0.187).
Improvement of baseline pain 3 days after ONB com-
pared between the different subtypes of facial pain yielded
nosigniﬁcant resultsinpairwise comparisons(mean percent
of baseline pain: trigeminal neuralgia 43.1 ± 38.8; trigem-
inal neuropathic pain 66.7 ± 38.8; persistent idiopathic
facial pain: 85.3 ± 23.5). Results of unpaired t tests are as
follows: trigeminal neuralgia versus trigeminal neuropathic
pain: p = 0.283; trigeminal neuralgia versus persistent idi-
opathic facial pain: p = 0.053; trigeminal neuropathic pain
versuspersistentidiopathicfacialpain:p = 0.375).Notably,
the comparison between improvement in patients with tri-
geminal neuralgia and persistent idiopathic facial pain mis-
sed signiﬁcance by a narrow margin.
Evaluation of the number of effective nerve blocks
yielded similar results. The total response rate was 13 out
Table 5 Results of occipital nerve block (ONB) in persistent idiopathic facial pain (FP)
ID Sides/mixture/
volume
Pre-ONB Post-ONB 3 days
Tenderness
over GON
Intensity
(VAS)
Hypa ¨sthesia
after ONB
% of pre-
ONB
pain
Intensity
(VAS)
Duration of
improvement
(days)
Response
(C50%)
Painful? Side
effects?
FP1_1 29 (30 mg L;
4m g
D/2.5 ml)
Ipsilateral 6/10 Right-,
left-
5 1/10 11 ? ––
FP1_2 29 (30 mg L;
4m g
D/2.5 ml)
None 4/10 Right-,
left-
40/100
a 4/10 0 – – –
FP1_3 29 (30 mg L;
4m g
D/2.5 ml)
Ipsilateral 7,5/10 Right-,
left-
0 0/10 7
§ ? ––
FP1_4 29 (50 mg
L(1%); 4 mg
D/6 ml)
None 6/10 Right-,
left-
80
% 5/10 0 – – –
FP2 19 (30 mg L;
4m g
D/2.5 ml)
Ipsilateral
(unilateral
block)
8/10 Left- 100
# 5/10 0 – – ?
FP3 29 (30 mg L;
4m g
D/2.5 ml)
Ipsilateral
contralateral
3,5/10 Right-,
left-
100 3,5/10 0 – – –
FP4_1 29 (30 mg L;
4m g
D/2.5 ml)
Ipsilateral
contralateral
8/10 Right-,
left-
100 8/10 0 – ? –
FP4_2 29 (50 mg
L(1%); 4 mg
D/6 ml)
Ipsilateral
contralateral
6/10 Right?,
left?
60
% 5/10 0 – – –
FP5 29 (50 mg
L(1%); 4 mg
D/6 ml)
Ipsilateral 7/10 Right-,
left-
100 7/10 0 – – –
Response was deﬁned as an improvement of at least 50% compared to pre-ONB pain. Sides: 1 indicates unilateral ONB ipsilateral to the side of
pain, 2 indicated bilateral ONB
L lidocaine, D dexamethasone
a As pain ratings were unchanged after ONB, improvement to 40% was considered implausible and response was consequently rated negative
with 100% of pre-ONB pain
# First follow-up after 4 days
% First follow-up after 6 days
§ Despite ongoing beneﬁt, duration of beneﬁcial effects was limited to 7 days as medication was changed after day 7
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12325 blocks (52%). In trigeminal neuralgia 6 out of 8
blocks (75%) were considered effective, in occipital
neuralgia 1 out of 1 block (100%). In trigeminal neuro-
pathic pain, 4 out of 7 blocks were beneﬁcial (57%), in
persistent idiopathic facial pain 2 out of 9 blocks were
effective (22%).
Seven responders were females and 4 males (mal-
e:female = 1:1.8), which is comparable to the entire
sample (1:1.9). Hypoesthesia ipsilateral to the pain was
present in 10 successful ONBs and 3 unsuccessful ONBs
(data on hypoesthesia were missing in TN1), no relevant
hypoesthesia was noted in 4 successful and 7 unsuc-
cessful ONBs (2 9 2 table with Fisher’s Exact test:
p = 0.095).
Pain ratings
Mean pain ratings for all patients (responders and non-
responders) were reduced by 50% (VAS ratings pre-
ONB 7.2, SD 2.4; post-ONB 3.6, SD 2.2; t test:
p = 0.001; Fig. 1). The therapeutic effect was even
higher in the subgroup of patients with trigeminal
neuralgia with a reduction of 66% (pre-ONB 7.3, SD
2.7; post-ONB 2.5, SD 1.6; t test: p = 0.01). In tri-
geminal neuropathic pain, a reduction of only 37% was
observed (pre-ONB 7.4, SD 2.8; post-ONB 4.7, SD 2.2;
t test: p = 0.086). Reduction of pain intensity was
lowest in patients with persistent idiopathic facial pain
with only 22% (pre-ONB 6.3, SD 1.7; post-ONB 4.9,
SD 1.9; t test: p = 0.140).
A comparison of net ONB effects on pain ratings (dif-
ference of pain ratings before and after ONB) between the
subgroups yielded no signiﬁcant results in unpaired t tests:
trigeminal neuralgia versus trigeminal neuropathic pain
p = 0.312; trigeminal neuralgia versus persistent idio-
pathic facial pain: p = 0.094; trigeminal neuropathic pain
versus persistent idiopathic facial pain: p = 0.406).
Sustained beneﬁt
Mean duration of clinical improvement (considering only
patients with at least 50% improvement on day 3) was
27 days (range 3–107, SD 38.1). A sustained beneﬁt
(deﬁned as continuous improvement of at least 50%) was
obtained in 3 patients who were followed-up for 69, 77 and
107 days (Fig. 3). Thereafter, follow-up was suspended. It is
noteworthy that all these patients suffered from craniofacial
neuralgias (2 with trigeminal and 1 with occipital neuralgia).
One of these patients (TN6) was able to successively reduce
all preventative medication over the course of 77 days
without recurrence of pain. As follow-up was eventually
stopped in patients with long-lasting beneﬁt (TNP4, TN6
and ON1), the number of days without improvement could
even be higher (so far none of these patients has contacted
our clinic for an appointment due to worsening of the
symptoms, although we cannot exclude that the patient
seeked further care at another specialized center).
Tenderness over the greater occipital nerve
Neck pain was not reported by any patient. Local tenderness
over the greater occipital nerve ipsilateral to the side of pain
was present in all but three patients (two patients with tri-
geminal neuropathic pain, one with trigeminal neuralgia) and
not tested in one patient (i.e. present in 83%). Contralateral
tenderness was present in eight patients and not tested in one
(i.e. present in 44%). A combination of the absent tenderness
over the greater occipital nerve and missing hypoesthesia
after ONB was found in only 2 unsuccessful blocks.
Effect of repetitive ONBs
In three patients, repetitive ONBs were performed. How-
ever, only one patient (TNP5) reported recurrent beneﬁt
after both blocks, while another patient (FP1) experienced
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Fig. 1 a Success rate of ONB among the different diagnoses. The
height of bars indicates total number of patients; the black parts
indicate patients with success. b Pain intensity ratings on a verbal
rating scale (VRS) before and after ONB in various facial pain
symptoms. Black bars indicate ratings before ONB, gray bars after
ONB. FP persistent idiopathic facial pain, TN trigeminal neuralgia,
TNP trigeminal neuropathic pain, ON occipital neuralgia
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123beneﬁcial effects after two of four ONBs. In another patient
(FP4), a second ONB was performed despite failure of the
initial block again without success.
Duration of attacks
In patients with trigeminal neuralgia, three patients repor-
ted shorter attacks, two patients an unchanged duration of
attacks and another slightly longer attacks. Due to missing
data, effects of ONB on attack duration could not be
evaluated in 2 out of 8 patients.
Susceptibility to triggers
The susceptibility to known triggers was lower in 3 out of 8
(38%) patients with trigeminal neuralgia and in 3 out of 6
patients with trigeminal neuropathic pain (50%) on the
third day post-ONB. It was unchanged in two patients with
trigeminal neuralgia and two with trigeminal neuropathic
pain and increased in 2 patients with trigeminal neuralgia
and 1 with trigeminal neuropathic pain. The only patient
with occipital neuralgia reported a persistent and complete
reduction of trigger factors after ONB with decline from
10/10 to 0/10. Trigger factors were not evaluated in
patients with persistent idiopathic facial pain.
Effect of unilateral blocks
Two patients who received unilateral ONBs did not
respond.
Effect of lidocaine dose
The amount of lidocaine and thus the applied volume
varied over the observed period. Initially, 30 mg lidocaine
was given routinely. Later, most patients received
40–50 mg. Distribution of response rates among various
lidocaine amounts was not dose speciﬁc: a positive
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including results of patients with sustained relief
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123response was observed in 0 out of 1 ONB with 20 mg
(0%), 10 out of 15 ONBs with 30 mg (67%), 3 out of 5
ONBs with 40 mg (60%) and 0 out of 4 ONBs with 50 mg
(0%).
In addition, no relation between the lidocaine dose and
the absence of hypoesthesia could be found. In 8 of 15
blocks (53%) with 30 mg lidocaine no hypoesthesia could
be found and in 2 of 4 blocks (50%) with 50 mg and
missing data in 1 patient. Hypoesthesia could always be
found in ONBs with 20 mg (1 block) and 40 mg (5 blocks)
lidocaine.
Effect of affected trigeminal branches
Positive response rates were reported in the only patient
with involvement of V1?2 (100%), in 2 out of 3 with
involvement of V1–3 and V2?3 (67%), 3 out of 9 with V2
(33%) and 2 out of 3 with V3 (66%), respectively. The only
patient with involvement of the greater occipital nerve
(C1–3) responded (100%).
Side effects
The injection procedure was rated painful by 2 out of 8
patients with trigeminal neuralgia (13%) and by one patient
each with trigeminal neuropathic pain (17%) and persistent
idiopathic facial pain (20%) resulting in a total of 4 out of
20 patients (20%). Transient and only mild ONB-related
side effects were observed in 10 of the 20 patients (50%,
see Table 6). Cranial ﬂush or heat sensation was the most
frequent side effects in 5 patients (25%), followed by a
transient and mild bleeding after the syringe was pulled out
in 2 patients (15%). All patients recovered completely
without sequelae. One patient (FP4) suffered from dizzi-
ness and increased sweating on the third day after the ﬁrst
ONB. These were regarded as prodromal symptoms of a
gastrointestinal infection, which was reported on the sixth
day post-ONB and thus unrelated to ONB. Mean age of
patients with side effects was 52 years (range 21–80 years,
SD 19.8) and thus younger than the mean age of the entire
cohort.
Discussion
In this chart review, the effects of occipital nerve blocks
were evaluated in 20 patients with craniofacial neuralgias
or neuropathic pain and persistent idiopathic facial pain.
All but one (occipital neuralgia) had second and/or third
division trigeminal pain. The mean response rate was 55%
(deﬁned as at least 50% reduction of original pain reported
by the patient) and was most effective in patients with
trigeminal neuralgia (75%), although results did not reach
statistical signiﬁcance. ONB was less effective in trigem-
inal neuropathic pain (50%) and persistent idiopathic facial
pain (20%).
Occipital nerve block reduced mean pain ratings sig-
niﬁcantly in the entire sample by 50% (again with greater
effects in neuralgias and less pronounced effects in tri-
geminal neuropathic pain and persistent idiopathic facial
pain). These effects lasted for an average of 27 days with a
sustained beneﬁt for up to 107 days in three patients (two
with trigeminal neuralgia and one with occipital neuralgia).
Our data have to be seen with caution as our study was
retrospective and open labeled. Groups were small and
composition of the lidocaine/dexamethasone mixture var-
ied. As such, these data mirror clinical routine and not a
controlled study; consequently we decided to report
descriptive statistics for most variables only. Despite these
limitations, we show striking differences in efﬁcacy of
ONB between different entities of facial pain. Patients with
Table 6 Side effects of occipital nerve blocks graded according to
their severity and outcome
Patient Side effect Severity Outcome
Related to ONB
TN1 Day 1: cranial heat sensation,
mild local bleeding after
removal of syringe
Mild Complete
remission
TN6 Day 0: mild transient
hypertension
Mild Complete
remission
TN8 Day 0: cranial heat sensation Mild Complete
remission
TNP1 Days 0–7: tenderness over
injection side
Mild Complete
remission
TNP2 Day 1: cranial heat sensation,
hypoesthesia left upper arm,
day 4: tenderness over
injection side
Mild Complete
remission
TNP3 Day 0: prolonged local bleeding
for few minutes after syringe
was pulled out
Mild Complete
remission
TNP4 Day 0: cranial heat sensation Mild Complete
remission
TNP5_1 Day 0: dull cervical pain (right
side)
Mild Complete
remission
TNP5_2 Day 0: bleeding after retrieving
the syringe for 10 s
Mild Complete
remission
TNP6 Day 0: mild headache Mild Complete
remission
FP2 Day 0: cranial ﬂush, local
tenderness over injection site
(left occiput)
Mild Complete
remission
Unrelated to ONB
FP4_1 Day 3: dizziness and increased
sweating, most likely prodome
of gastrointestinal infection
reported on day 6
Mild Complete
remission
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123idiopathic facial pain responded barely, while those with
craniofacial neuralgia showed highest response rates.
Pathophysiological implications
It has been shown in anatomical studies that A-delta and
C-ﬁber afferents from trigeminal and occipital (C1-3)
nerve branches terminate in the trigemino-cervical com-
plex (TCC) [22–24] and that painful stimulation of either
structure leads to up-regulation of metabolic activity and
release of c-fos [24, 25]. Convergent neurons in the TCC
have input not only from ipsi- but also from contralateral
cervical afferents [16]. In our cohort, tenderness over the
greater occipital nerve contralateral to the side of pain was
present in 44% of all patients. As patients suffered from
strictly unilateral and side-locked pain, this implies a
clinically relevant bilateral connection. Based upon these
ﬁndings, occipital nerve stimulation (ONS) is usually
implanted bilaterally to avoid side changes observed in
patients with cluster headache receiving ipsilateral ONS
[26]. Therefore, bilateral nerve blocks could have higher
efﬁcacy and should be preferred if potential side effects do
not preclude this option.
The phenomenon of referred pain in the occipital region
upon nociceptive trigeminal activation has been described
in patients with primary headaches such as migraine and
cluster headache [27, 28]. The surprisingly high number of
patients with tenderness at the greater occipital nerve
ipsilateral to but well outside the painful area in our study
is noteworthy. It suggests an important role of trigemino-
cervical convergence of nociceptive afferents also in syn-
dromes with involvement of the second and third (V2 and
V3) trigeminal branch and could explain ONB efﬁcacy in
these conditions.
However, recent studies imply that ONB effects could
be mediated by an additional mechanism. In rodents and
human cadavers nociceptive collaterals of the nervus
spinosus (meningeal branch of the mandicular nerve,
formed by neurons from the maxillary and mandibular part
of the Gasserian ganglion) were found to innervate both the
dura mater and occipital periost and neck muscles [29].
Based on these observations, at least partial effects of
ONBs in craniofacial pain could be conveyed by direct
inhibition of extracranial collaterals of the maxillary and
mandibular nerve. In addition, these results further cor-
roborate the above-mentioned hypothesis that nociceptive
V2 and V3 afferents converge with high cervical noci-
ceptive afferents.
The observation that effects are most pronounced in
craniofacial neuralgia and trigeminal neuropathic pain
rather than in persistent idiopathic facial pain would argue
in favor of different pathophysiological models. While
craniofacial neuralgia [30] and trigeminal neuropathic pain
[31, 32] are neuropathic pain syndromes with central
components, no coherent construct exists in persistent
idiopathic facial pain although one study reported neuro-
pathic changes in patients with facial pain [31]. Interest-
ingly, cortical somatosensory representation of the face
was not altered in patients with persistent idiopathic facial
pain and modalities of quantitative sensory testing were not
affected [33]. It was therefore concluded that persistent
idiopathic facial pain has elements of a central pain syn-
drome not sustained by somatosensory processing from the
affected region.
Technical considerations
Deﬁnition of response
Response was deﬁned as an at least a 50% decrease in pain
after ONB as judged by the patients in percent of baseline
pain. Evaluation of interventional procedures based on
subjective assessment by the patient is certainly contro-
versial. Facial pain syndromes differ substantially in their
temporal proﬁles (constant versus intermittent pain), pain
characteristics (burning versus stabbing or lancinating
pain) and other factors like reduced susceptibility to trig-
gers. The above criterion had thus been chosen as standard
in a clinical setting to increase comparability between
groups and simplify evaluation for the patient. Moreover,
reports of pain intensity yielded similar results.
Role of hypoesthesia
Occipital hypoesthesia after ONB was present in 76% of
the patients. Hypoesthesia was absent in 8 out of 12
unsuccessful ONBs and present in 9 of 13 successful ONBs
(which was statistically not signiﬁcant). One potential
explanation for missing hypoesthesia could be that ONBs
were misplaced (as ONBs induce conduction blocks with
consecutive sensory loss of the innervated area) or due to
the varying amount of lidocaine/cortisone. However, there
was no obvious correlation between the degree of hypo-
esthesia and the amount of lidocaine used.
Our data do at present not support a predictive role of
hypoesthesia for ONB efﬁcacy. This is in line with a pre-
vious study on cluster headache, migraine and new daily
persistent headache [9] which found no signiﬁcant associ-
ation between occipital hypoesthesia and ONB efﬁcacy.
Composition of anesthetic mixture
Lidocaine has been used frequently in ONB studies [2–6, 9,
10, 12]. Despite our positive results, we cannot exclude that
results would have been better with bupivacaine [7, 34]. It
not only has a signiﬁcantly longer half-life than both
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However, it is doubtful if the half-life of the local anes-
thetic is crucial, as the clinical effects, when present, out-
lasted the local anesthetics’ half-life by far. Likewise, long
acting steroids such as triamcinolon could be more
advantageous in clinical practice.
Regarding the ideal composition of the injection it is not
known whether a local anesthetic or corticosteroid alone or
a combination of both is more effective. While some
studies used either local anesthetics or corticosteroids alone
(see [14] for review), the additional use of a steroid is
important for ONB efﬁcacy either by prolonging effects of
local anesthetics or by acting independently on nerve
activity [10, 13, 35]. The additional use of opioids and
clonidine has been propagated but would need further
studies to fully evaluate their therapeutic potential [3, 4].
Our limited data do not support dose-dependent effects
of lidocaine within the limited range used in our study,
which is in line with previous studies [36]. However,
methylprednisolone was less effective in higher doses [37].
Injection site
Assuming that tenderness over the occipital region suggests
vicinity to the greater occipital nerve, ONBs should have
been placed correctly in our study in all but four patients.
Although the greater occipital nerve is the main target in all
published studies, the exact injection site varies substan-
tially among the published studies. In some studies, ONBs
were given below the occipital ridge [10], others have used
higher and more lateral locations [9]. However, the ana-
tomical course of the greater occipital nerve shows sig-
niﬁcant inter- and intra-individual differences [38]. In a
human post mortem study, the exit point of the greater
occipital nerve was located between 3 and 28 mm laterally
to the occipital protuberance and 5–18 mm below the in-
termastoid line. Fixed injection schemes could be too static
and may result in reduced efﬁcacy of ONBs. For optimi-
zation, the use of nerve stimulators to locate the correct
position is one option [2–4], ultrasound-guided techniques
[39, 40] are another. For feasibility, we would suggest
locating the exact position by tenderness on palpation (also
referred to as TOP) which is a more practical approach (see
[34] for review).
Safety aspects
In our cohort, side effects were generally rare, mild, tran-
sient and completely remitting (see Table 6). No severe
side effects occurred. Accidental intravenous injections of
high dose local anesthetics have been reported to cause
mild (such as lightheadedness or metallic taste) to severe
(such as cardiac arrhythmia or epileptic seizures) adverse
effects [41]. It should also be borne in mind that cutaneous
atrophy has been reported in 1–14% of the patients
receiving steroid injections [42]. Despite these rare side
effects, ONB is a safe procedure in the hands of trained
physicians.
Limitations
Due to the design of our study as a retrospective chart
review, several methodological shortcomings are inherent.
As placebo effects observed in headache management can
reach up to 50% in individuals [43] and invasive proce-
dures are likely to have even higher placebo rates, we
cannot exclude that our observations are mainly driven by
placebo response. Nevertheless, sustained beneﬁts in some
patients lasting up to 2 months or more argue against pure
placebo-mediated effects. Similar latencies have been
observed in a small double-blind trial in patients with
cervicogenic headache, who showed signiﬁcantly pro-
longed pain-free periods after repeated occipital and
supraorbital nerve block [3] and a single case with tri-
geminal neuropathic pain with substained beneﬁt for
4 months [19]. Likewise, in a double-blind placebo-con-
trolled trial a single suboccipital injection of betametha-
sone in patients with cluster headache led to prolonged
effects with remission periods of up to 26 months [10].
Fluctuations in the natural course (as can be frequently
seen in trigeminal neuralgia as an episodic disease) cannot
be excluded and would require a controlled design. As only
patients with complete datasets were included, this infers
the risk of selection bias. In addition, results were not
corrected for psychological comorbidity as this would be
beyond the scope of a chart review.
Implications for clinical practice and future
perspectives
Treating patients with facial pain is challenging and may
involve combining several drugs at higher dosages. Espe-
cially in elderly and frail patients preventive medication is
often problematic as most of them are already on poly-
pharmacy. In a sample of elderly internal patients in
Austria, the mean number of drugs taken on admission was
7.5 per patient [44]. Adding more drugs can induce severe
side effects and cause unpredictable interactions. Espe-
cially anticonvulsants (carbamazepin, oxcarbazepine, phe-
nytoin, and valproate) or tricyclics (amitriptyline) can be
hazardous in elderly as they induce or inhibit drug
metabolism. Furthermore, most of these routinely used
drugs cause side effects particularly problematic in elderly
such as ataxia, arrhythmia and cognitive impairment. Thus,
ONBs could be beneﬁcial as a well-tolerated add-on ther-
apy to bridge changes in preventive therapy and can lead to
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important that results of this small retrospective trial should
be interpreted with caution as subjects were not prospec-
tively enrolled into a randomized placebo-controlled blin-
ded trial.
Conclusion
Occipital nerve block seems to be more effective in tri-
geminal neuralgia than in trigeminal neuropathic pain and
persistent idiopathic facial pain. It seems plausible to use
this method not only in patients with headache but also in
patients with craniofacial neuralgias. Given that side
effects are mild and that the procedure is minimally inva-
sive, we suggest using this method before considering more
invasive approaches such as thermocoagulation or vascular
decompression. Moreover, it could be helpful for transient
prophylactic treatment during dose escalation of ﬁrst-line
drugs (such as carbamazepine). However, as placebo
effects are known to be high in chronic pain, results have to
be interpreted with caution and randomized controlled
studies are mandatory to conﬁrm these preliminary results.
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